FDA authorizes COVID-19 vaccine booster shots

By The Science Advisory Board staff writers

October 21, 2021 -- Johnson & Johnson and Moderna have received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for booster shots of their COVID-19 vaccines.

Johnson & Johnson COVID-19 vaccine booster shots are authorized for adults ages 18 and older at least two months following primary vaccination and for eligible individuals who received a different authorized or approved COVID-19 vaccine.

The Johnson & Johnson booster shot will be the same formulation and dosage as the primary shot. The company has a sufficient supply to support boosting in the U.S. for all those who received primary vaccination with the Johnson & Johnson COVID-19 vaccine, the company said.

Moderna's EUA covers the use a booster dose of its COVID-19 vaccine (mRNA-1273) at the 50 µg dose level for people ages 65 and older, people ages 18 to 64 who are at high risk of severe COVID-19, and people ages 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2.

Moderna's booster dose is to be administered at least six months after completion of a primary series and is also authorized for people who completed a primary vaccination with other authorized or approved COVID-19 vaccines.

The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices was expected meet on October 21 to provide a potential recommendation on the rollout of COVID-19 boosters.

Novavax COVID-19 vaccine booster appears effective after primary vaccination
Novavax announced preliminary data indicating that a single booster dose of the company's recombinant nanoparticle protein-based COVID-19 vaccine drew...
Novavax touts COVID-19 vaccine results
Novavax is highlighting study results that demonstrate the efficacy of its COVID-19 vaccine, NVX-CoV2373, as well as a new COVID-19 vaccine it is developing...
Pfizer to study pneumococcal, COVID-19 vaccine combo in older adults
Pfizer has launched a study that is investigating the coadministration of the company's pneumococcal vaccine (20vPnC) and its Pfizer-BioNTech COVID-19...
Clover highlights preclinical data for COVID-19 vaccine candidate
Clover Biopharmaceuticals said that its second-generation, protein-based COVID-19 vaccine candidate has demonstrated in preclinical testing that it can...
Sanofi, GSK COVID-19 vaccine to advance to phase III trials
Sanofi and GlaxoSmithKline's (GSK's) adjuvanted, recombinant COVID-19 vaccine candidate produced strong rates of neutralizing antibody responses in all...

Copyright © 2021 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter